Thieno [2,3-b] pyridine compounds with mGluR activity
AssigneeRichter Gedeon Nyrt.
InventorsIstvan Gyertyan, Katalin Nogradi, Ottilia Elekes, Monika Vastag, Amrita Agnes Bobok, Katalin Saghy
Life of this patent
Estimating the term…
Abstract
Provided herein are Thieno[2,3-b]pyridine compounds with mGluR activity. Also provided herein are processes and intermediates for the preparation of the Thieno[2,3-b]pyridine compounds, pharmaceutical compositions containing these compounds, and the use of these compounds in treatment, therapy, and/or prevention of conditions which require modulation of mGluR1 and mGluR5 receptors.
Claims16
A compound of formula (I):
- or a pharmaceutically acceptable salt thereof,
- wherein X is Cl or F.
A compound:
- 5-Amino-2-(3-cyano-5-fluoro-benzenesulfonyl)-3-(3-fluorophenyl)-thieno[2,3-b]-pyridine or a pharmaceutically acceptable salt thereof.
A process for the preparation of a compound of formula (I):
- or a pharmaceutically acceptable salt thereof,
- wherein X is Cl or F;
- comprising:
- nitration of a compound of formula (II);
- followed by a reduction and then a Suzuki coupling reaction to obtain a compound of formula (I).
A pharmaceutical formulation, comprising:
- a therapeutically-effective amount of a compound of formula (I)
- or a pharmaceutically acceptable salt thereof,
- wherein X is Cl or F;
- and at least one of physiologically acceptable diluents, excipients or inert carriers.
A compound:
- 5-Amino-2-(3-cyano-5-fluoro-benzenesulfonyl)-3-(3-chlorophenyl)-thieno[2,3-b]-pyridine, or a pharmaceutically acceptable salt thereof.
A pharmaceutical formulation, comprising:
- 5-Amino-2-(3-cyano-5-fluoro-benzenesulfonyl)-3-(3-fluorophenyl)-thieno[2,3-b]-pyridine or a pharmaceutically acceptable salt thereof, and at least one of physiologically acceptable diluents, excipients or inert carriers.
A pharmaceutical formulation, comprising:
- 5-Amino-2-(3-cyano-5-fluoro-benzenesulfonyl)-3-(3-chlorophenyl)-thieno[2,3-b]-pyridine or a pharmaceutically acceptable salt thereof, and at least one of physiologically acceptable diluents, excipients or inert carriers.
Dependencies are inferred from the claim text.